Elizabeth Goodwin. Investors: Elizabeth Goodwin VP Investor Relations +1 781 460 1784. Galapagos NV (NASDAQ: GLPG) . ET). NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG).). Onno will retire and make way for a new CEO . Investor Relations Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium Tel: +32 15 34 29 00 Email: ir@glpg.com. Monday to Friday from 8:30am to 6pm CEST +33 (0)2 51 85 67 89. Monica Currier Real Estate Success Manager at North&Co. Phoenix, AZ. Mechelen, Belgium; 6 January 2022, 15.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022. Tel +1 781 460 1784. She previously was Investor Relations Officer at Mithra Pharmaceuticals SA and Co-Chief Executive Officer for KBC Securities USA, Inc. She received a graduate degree from Trinity College Dublin and a doctorate from Katholieke Universiteit Leuven. Galapagos NV American Depositary Shares (GLPG) Nasdaq Listed. This release may contain forward-looking statements. Sofie Van Gijsel Senior Director Investor Relations +1 781 296 1143. Galapagos NV (NASDAQ:GLPG) Q3 2020 Results Conference Call November 6, 2020 8:00 AM ET. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Forward-looking statements The presentation will be a live audio webcast and can be accessed via the following link. Mechelen, Belgium; 13 January 2022, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 30,000 subscription rights under a new employee subscription right plan. Media: Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900. Galapagos Contacts: Investors: Elizabeth Goodwin VP Investor Relations +1 781 460 1784 Sofie Van Gijsel Senior Director Investor Relations +32 485 19 14 15 ir@glpg.com. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Mechelen, Belgium; 13 January 2022, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 30,000 subscription rights Sofie Van Gijsel Senior Director Investor Relations +1 781 296 1143. Mechelen, Belgium; 6 January 2022, 15.30 CET - Galapagos NV ((Euronext &, NASDAQ:GLPG) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022. VP Investor Relations +1 781 460 1784 Sofie Van Gijsel Senior Director Investor Relations +1 781 296 1143 Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com Media: Anna Gibbins WILMINGTON, Mass.--(BUSINESS WIRE)--Mar. Mechelen, Belgium; 6 January 2022, 15.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022. Evelyn Fox Director Executive Communications +31 65 3591 999. communications@glpg.com. Investors: Elizabeth Goodwin VP Investor Relations +1 781 460 1784. Investors should consult a financial advisor/financial consultant before making any investment decisions. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Mechelen, Belgium; 26 January 2022, 22.40 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 1,000,000 subscription rights under a new subscription right plan for the benefit of a member of the personnel of the Company. Investor Relations Sign Up for Email Alerts. On 13 January 2022, the supervisory board of Galapagos approved a subscription right plan intended for an employee of a subsidiary of the Company (not intended . Data is currently not available. Corporate Profile. Sandra Cauwenberghs Director Investor Relations +32 495 58 . Annual Report. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. Galapagos NV Investor Relations Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium Tel: +32 15 34 29 00 Email: ir@glpg.com A digital version of this report is available on our website, www.glpg.com. Change +0.15€. Las Vegas, NV. New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). . Galapagos NV (NASDAQ:GLPG) Q3 2020 Results Conference Call November 6, 2020 8:00 AM ET. I am Sofie Van Gijsel, Investor Relations, representing the reporting team at Galapagos. Mechelen, Belgium; 30 August 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces the planned retirement of CEO Onno van de Stolpe.. Onno van de Stolpe co-founded Galapagos in 1999 and built and led the company as CEO from its early R&D days through to the commercial launch of Jyseleca ® (filgotinib) in Europe.Onno will retire and make way for a new CEO . Elizabeth Goodwin - Investor Relations. An audio replay of today's analyst call hosted by IMCD's CEO and CFO, will be made available later today. Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603 communications@glpg.com. Investors. 8900 Ieper - Belgium. ET). Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. -2.80 (-4.09%) DATA AS OF Feb 02, 2022. Forward-looking statements. Forward-looking statements. Presently, Sofie Van Gijsel is Director-Investor Relations of Galapagos NV. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. Galapagos NV. Galapagos Investors: Elizabeth Goodwin VP IR & Corporate Communications +1 781 460 1784 Sofie Van Gijsel Director IR +32 485 19 14 15 ir@glpg.com Galapagos Media: Evelyn Fox Director Communications +31 6 53 591 999 communications@glpg.com FORWARD LOOKING STATEMENTS Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603. Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143 Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com Media: Marieke Vermeersch Head of Corporate Communications +32 479 49 06 03 communications@glpg.com Forward-looking statements This release may contain forward-looking statements. This release may contain forward-looking statements. $65.70. Sangean Palmer . We have an international investor base, with a long term commitment to the biotech industry. Galapagos NV ( NASDAQ:GLPG) Q3 2021 . Investors: Elizabeth Goodwin VP Investor Relations +1 781 460 1784. Motley Fool Transcribers. Owner at Monserrat Galapagos Cruises . Intermediaries & Investors US: +1 212 723 5435 UK: +44 207 500 2030. citiadr@citi.com. Onno van de Stolpe co-founded Galapagos in 1999 and built and led the company as CEO from its early R&D days through to the commercial launch of Jyseleca® (filgotinib) in Europe. Overview Career Highlights Find out more. NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Galapagos NV ("Galapagos" or the "Company") (NASDAQ:GLPG). Media: Marieke Vermeersch Head of Corporate . Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603 communications@glpg.com. Sandra CauwenberghsDirector Investor Relations+32 495 58 46 63 ir@glpg.com. About the Author. Forward-looking statements Bart will join the Executive Committee of Galapagos and be responsible for Finance, Investor Relations, IT, and Purchasing. Add to Watchlist. Elizabeth Goodwin VP Investor Relations +1 781 460 1784 Sofie Van Gijsel Senior Director Investor Relations . Pharming is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. Latest Presentations February 2022 Corporate Presentation. Investor Relations. Elizabeth Goodwin - Investor Relations. Galapagos NV Onno van de Stolpe Chief Executive Officer Tel: +31 6 2909 8028 Elizabeth Goodwin Director Investor Relations Tel: +31 6 2291 6240 Email Contact. Investor Relations. Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 3 December 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a s. Nasdaq 100. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143 Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603 communications@glpg.com The Latin American index gained 0.5% to 192.43, while the emerging markets index sank 1.1% to 335.72. . Invesco Distributors, Inc., is the US distributor for Invesco Ltd.'s Retail Products, Collective Trust Funds and CollegeBound 529. Media: Marieke Vermeersch Head of . Lexicon is the only company to have systematically studied the role and function of . Jennifer Levin Dr. Hoekema currently also serves as a Member of the Supervisory Board of Mimetas B.V. 75.65€. Our 2021 first nine months results are now live and hold the latest available financial information. Mechelen, Belgium; 6 January 2022, 15.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40 th A nnual J.P. Morgan Healthcare Conference on January 10-13, 20 22. Sandra Cauwenberghs Director Investor Relations +32 495 58 . 31, 2014-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. 81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21:dvklqjwrq ' & )250 ) 0dunrqh 5(*,675$7,2167$7(0(1738568$17726(&7,21 e 25 j 2)7+(6(&85,7,(6(;&+$1*($&72) Below you can download the press release and analyst presentation. Mr. A replay of the webcast will be . Galapagos NV was among those whose ADRs traded actively. Bart Filius has over 13 years' experience at Sanofi. 10 JAN 2022 . Mechelen, Belgium; 11 January 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc. Galapagos NV GLPG announced results from several early- to mid-stage studies evaluating two inflammatory candidates — GLPG3970 and GLPG3667 — with different mechanism of action. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. (MFTranscribers) Nov 5, 2021 at 2:01PM. 7980. The presentation will be a live audio webcast and can be accessed via the following link. Galapagos NV: Gilead holds 25.54% of Galapagos shares. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143 Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603 communications@glpg.com Forward-looking statements. 16 FEB 2022 12:00 PM EST 16 FEB 2022 12:00 PM EST SVB Leerink Global Healthcare Conference - Fireside Chat. Investors. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing . January 11, 2021, 4:01 PM EST . Investors: Elizabeth Goodwin. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 [email protected] Media: Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Last Price 75.50€. Media: Carmen Vroonen Head of Internal & External Communications & Public Affairs +32 473 824 874 Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900 Sofie Van Gijsel. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. Company Participants. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Sofie Van Gijsel Senior Director Investor Relations +1 781 296 1143. Elizabeth Goodwin VP Investor Relations +1 781 460 1784 Sofie Van Gijsel Senior Director Investor Relations . He has 20 years of biotech experience from positions at Molecular Probes Europe, Crucell, DSM Life Sciences and MOGEN and Genentech, Inc. Age: 57 Ph.D. 32 1 534 29 00 https://www.glpg.com. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603 communications@glpg.com Forward-looking . Add to Portfolio. Galapagos is progressing multiple programs in inflammation, fibrosis, and kidney diseases. Evelyn Fox Director Executive Communications +31 65 3591 999 . Media: Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900 Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603 communications@glpg.com. Janice Viverette . Shareholders, investors and other interested parties with questions related to the Picanol Group may contact: Frederic Dryhoel. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. Such investors are advised to . 2800 Mechelen, Belgium. Sofie Van GijselHead of Investor Relations +1 781 296 1143. The presentation will be a live audio webcast and can be accessed via the following link. A digital version of this report is available on our website, www.glpg.com. View Presentation 1.4 MB. The acquisition positions Charles River as a full service, early-stage contract research organization . Generaal De Wittelaan L11 A3. Investor contacts. Previously, he was Chief Financial Officer of Cambridge University Hospitals from 2007 to 2013, and of Galapagos NV between 2006 and 2007, during which time he played a key role in several merger and acquisition projects to build the services division. Mechelen, Belgium; 30 August 2021, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces the planned retirement of CEO Onno van de Stolpe. Vice President Investor Relations. Sofie Van Gijsel. Investors: Elizabeth Goodwin VP Investor Relations +1 781 460 1784. Heineken Holding N.V. Steverlyncklaan 15. Senior Director Investor Relations +1 781 296 1143. Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. VP Investor Relations +1 781 460 1784. Events. Evelyn Fox Director Executive Communications +31 65 3591 999. communications@glpg.com. Senior Director Investor Relations +1 781 296 1143. Onno van de Stolpe, CEO, will present on Thursday, January 13 at 14.15 CET (8.15 a.m. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 [email protected] Media: Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900 Galapagos NV • Annual Report 2020. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. The Belgian pharmaceutical research . Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG. Investors who purchased Galapagos securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com . VP Investor Relations +1 781 460 1784. This release may contain forward-looking statements. Onno van de Stolpe, CEO, will present on Thursday, January 13 at 14.15 CET (8.15 a.m. Delayed by 15 minutes. Media Contact: OTC Markets Group Inc., +1 (212) 896-4428, [email protected] Contact Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. We will use reasonable efforts to ensure the accuracy of the digital version, but do not assume responsibility if inaccuracies or inconsistencies . Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603. Mechelen, Belgium; 6January 2022, 15.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022. Onno van de Stolpe - Chief Executive Officer . Email: ir@glpg.com. GLPG earnings call for the period ending September 30, 2021. Contact Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143. Mechelen, Belgium; 2 February 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the European Crohn's and Colitis Organization (ECCO) annual congress taking place 16-19 . Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ, all with the ticker symbol GLPG. Mechelen, Belgium; 2 February 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the European Crohn's and Colitis Organization (ECCO) annual congress taking place 16-19 . Galapagos NV: Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference . About Galapagos Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Image source: The Motley Fool. Sofie Van Gijsel Senior Director Investor Relations +1 781 296 1143. Mechelen, Belgium; 6 January 2022, 15.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40th Annual J . Media: Marieke Vermeersch Head of Corporate Communication +32 479 490 603. communications@glpg.com Go to Investor news. +32 (0)57 222 364. frederic.dryhoel@picanol.be. Senior Director Investor Relations. Société Générale Securities Services - Ordinary Shares contact information Call center in English and French. Corporate Communication Manager. Investors should undertake their own diligence and carefully evaluate companies before investing. Mobile: +1 781 296 1143. ir@glpg.com. Director Investor Relations +32 495 . Sandra Cauwenberghs. Company Participants. Investors: Sofie Van Gijsel Head of Investor Relations +1 781 296 1143 Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com Media: Marieke Vermeersch Head of Corporate Communications +32 479 49 06 03 communications@glpg.com Forward-looking statements This release may contain forward-looking statements. Media: . This release may contain forward-looking statements. This recorded webcast is accessible via the Galapagos website homepage and will be available for downloads. Onno van de Stolpe, CEO, will present on Thursday, January 13 at 14.15 CET (8.15 a.m. Marieke Vermeersch Head of Corporate Communication +32 479 490 603 [email protected] Forward-looking statements Get updates. Business Description Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a . Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Onno van de Stolpe - Chief Executive Officer . Forward-looking statements. Sofie Van Gijsel Senior Director Investor Relations +1 781 296 1143. ET). Contact Investors: Sofie Van Gijsel Senior Director Investor Relations +1 781 296 1143 Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com Galapagos NV . Sandra Cauwenberghs Director Investor Relations +32 495 58 46 63 ir@glpg.com. Realtor and Investor Phoenix, AZ. On 26 January 2022, the supervisory board of Galapagos approved "Subscription Right Plan 2022 (B . Discover our shareholder structure, share prices, key market ratios past and present, how we reward our shareholders with dividends and other information/tools.
Remote Control Marvel Spider-man 1:14 Buggy, Lexington Park At Westchase, New Barrackpore Municipality Map, Tripit: Travel Planner, Great Pyrenees Bernese Mountain Dog For Sale Near Me,
Projekt i realizacja: viscount crossword clue 3 letters
